Proportion of women who exprienced amenorrhea at Final Month3-5,7,11*

Percentage of women with amenorrhea was a nonranked secondary endpoint. These results were not controlled for multiplicity. Nominal values presented are not controlled for type 1 error.

ELARIS UF-2

ORIAHNN

53%

(n=172)

Placebo

5%

(n=85)


Results were similar in ELARIS UF-1 [ORIAHNN (n=183): 48%, placebo (n=91): 4%].

Amenorrhea was defined as having zero bleeding or spotting at Final Month*, which was a 28-day interval